FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979897420> ?p ?o ?g. }

• W2979897420 endingPage "3269" @default.
• W2979897420 startingPage "3269" @default.
• W2979897420 abstract "Abstract The impact of fluorescence in-situ hybridization (FISH) on outcome in AL amyloidosis remains uncertain. We analyzed the response and overall survival (OS) of 692 AL amyloidosis patients with available FISH testing at diagnosis. First line treatment was categorized as autologous stem cell transplant or three non-transplant regimens (melphalan-based; bortezomib-based, and immunomodulatory drug (IMiD)-based). Forty-nine percent of patients had t(11;14), 37% del 13q/monosomy 13 and 19% had trisomy/tetrasomy. Analysis by abnormality type was restricted to t(11;14) and trisomy/tetrasomy sub-groups as chromosome 13 abnormalities were commonly associated with the other abnormalities. Patients with t(11;14) had lower rate of very good partial response or better (≥VGPR) compared to those lacking t(11;14) (56% vs 70%, P=0.001). By regimen stratification, this difference was maintained for bortezomib-based (52% vs 77%; P=0.004) and IMiD-based therapy (13% vs 54%; P=0.04) (Figure 1). Patients with trisomy/tetrasomy had no difference in the rate of ≥VGPR compared to those who did not (66% vs 63%, P=0.62), with no difference within regimen types. OS was similar between t(11;14)-positive and negative patients (median 43 vs 57 months; P=0.58). However, sub-analysis by regimen type showed a significantly inferior OS among t(11;14)-positive bortezomib-treated patients (median 15 vs 27 months; P=0.05) and t(11;14)-positive IMiD-treated patients (median 12 vs 32 months; P=0.05) (Figure 2). Among t(11;14)-positive bortezomib-treated patients, the OS difference was maintained among favorable-prognosis patients, but was absent for poor-prognosis sub-groups (Table). Trisomy/tetrasomy was associated with inferior OS (median 29 vs 69 months; P=0.001), a difference that was maintained for melphalan (median 15 vs 32 months; P=0.01) and borderline significance for bortezomib (median 14 vs 38 months; P=0.09). Multivariate analysis confirmed an independent effect on OS for trisomy/tetrasomy in the study cohort and for t(11;14) among bortezomib-treated patients. FISH analysis is essential in newly diagnosed AL amyloidosis, as it provides prognostic information among treatment groups and may influence the selection of induction treatment. Patients with t(11;14) should be considered for ASCT at diagnosis. Disclosures Dispenzieri: Celgene: Research Funding; Alnylam: Research Funding; pfizer: Research Funding; Prothena: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Jannsen: Research Funding. Kumar:Glycomimetics: Consultancy; AbbVie: Research Funding; Array BioPharma: Consultancy, Research Funding; Kesios: Consultancy; Onyx: Consultancy, Research Funding; Noxxon Pharma: Consultancy, Research Funding; BMS: Consultancy; Skyline: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Research Funding; Sanofi: Consultancy, Research Funding; Millennium: Consultancy, Research Funding; Celgene: Consultancy, Research Funding. Kapoor:Amgen: Research Funding; Takeda: Research Funding; Celgene: Research Funding." @default.
• W2979897420 created "2019-10-18" @default.
• W2979897420 creator A5001453763 @default.
• W2979897420 creator A5004220089 @default.
• W2979897420 creator A5007747233 @default.
• W2979897420 creator A5012403700 @default.
• W2979897420 creator A5012884078 @default.
• W2979897420 creator A5016853434 @default.
• W2979897420 creator A5023193953 @default.
• W2979897420 creator A5026574827 @default.
• W2979897420 creator A5029802364 @default.
• W2979897420 creator A5033220547 @default.
• W2979897420 creator A5035289098 @default.
• W2979897420 creator A5036150860 @default.
• W2979897420 creator A5051470930 @default.
• W2979897420 creator A5052346975 @default.
• W2979897420 creator A5056260546 @default.
• W2979897420 creator A5068637846 @default.
• W2979897420 creator A5072502164 @default.
• W2979897420 creator A5076611748 @default.
• W2979897420 creator A5077686486 @default.
• W2979897420 creator A5079007941 @default.
• W2979897420 creator A5090694142 @default.
• W2979897420 date "2016-12-02" @default.
• W2979897420 modified "2023-09-29" @default.
• W2979897420 title "Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category" @default.
• W2979897420 doi "https://doi.org/10.1182/blood.v128.22.3269.3269" @default.
• W2979897420 hasPublicationYear "2016" @default.
• W2979897420 type Work @default.
• W2979897420 sameAs 2979897420 @default.
• W2979897420 citedByCount "0" @default.
• W2979897420 crossrefType "journal-article" @default.
• W2979897420 hasAuthorship W2979897420A5001453763 @default.
• W2979897420 hasAuthorship W2979897420A5004220089 @default.
• W2979897420 hasAuthorship W2979897420A5007747233 @default.
• W2979897420 hasAuthorship W2979897420A5012403700 @default.
• W2979897420 hasAuthorship W2979897420A5012884078 @default.
• W2979897420 hasAuthorship W2979897420A5016853434 @default.
• W2979897420 hasAuthorship W2979897420A5023193953 @default.
• W2979897420 hasAuthorship W2979897420A5026574827 @default.
• W2979897420 hasAuthorship W2979897420A5029802364 @default.
• W2979897420 hasAuthorship W2979897420A5033220547 @default.
• W2979897420 hasAuthorship W2979897420A5035289098 @default.
• W2979897420 hasAuthorship W2979897420A5036150860 @default.
• W2979897420 hasAuthorship W2979897420A5051470930 @default.
• W2979897420 hasAuthorship W2979897420A5052346975 @default.
• W2979897420 hasAuthorship W2979897420A5056260546 @default.
• W2979897420 hasAuthorship W2979897420A5068637846 @default.
• W2979897420 hasAuthorship W2979897420A5072502164 @default.
• W2979897420 hasAuthorship W2979897420A5076611748 @default.
• W2979897420 hasAuthorship W2979897420A5077686486 @default.
• W2979897420 hasAuthorship W2979897420A5079007941 @default.
• W2979897420 hasAuthorship W2979897420A5090694142 @default.
• W2979897420 hasConcept C104317684 @default.
• W2979897420 hasConcept C126322002 @default.
• W2979897420 hasConcept C159654299 @default.
• W2979897420 hasConcept C203014093 @default.
• W2979897420 hasConcept C2776229224 @default.
• W2979897420 hasConcept C2776364478 @default.
• W2979897420 hasConcept C2777478702 @default.
• W2979897420 hasConcept C2777542201 @default.
• W2979897420 hasConcept C2778249689 @default.
• W2979897420 hasConcept C2779551797 @default.
• W2979897420 hasConcept C2779672484 @default.
• W2979897420 hasConcept C2780189214 @default.
• W2979897420 hasConcept C2781413609 @default.
• W2979897420 hasConcept C30481170 @default.
• W2979897420 hasConcept C36394416 @default.
• W2979897420 hasConcept C53226629 @default.
• W2979897420 hasConcept C54355233 @default.
• W2979897420 hasConcept C55493867 @default.
• W2979897420 hasConcept C71924100 @default.
• W2979897420 hasConcept C86803240 @default.
• W2979897420 hasConcept C90924648 @default.
• W2979897420 hasConceptScore W2979897420C104317684 @default.
• W2979897420 hasConceptScore W2979897420C126322002 @default.
• W2979897420 hasConceptScore W2979897420C159654299 @default.
• W2979897420 hasConceptScore W2979897420C203014093 @default.
• W2979897420 hasConceptScore W2979897420C2776229224 @default.
• W2979897420 hasConceptScore W2979897420C2776364478 @default.
• W2979897420 hasConceptScore W2979897420C2777478702 @default.
• W2979897420 hasConceptScore W2979897420C2777542201 @default.
• W2979897420 hasConceptScore W2979897420C2778249689 @default.
• W2979897420 hasConceptScore W2979897420C2779551797 @default.
• W2979897420 hasConceptScore W2979897420C2779672484 @default.
• W2979897420 hasConceptScore W2979897420C2780189214 @default.
• W2979897420 hasConceptScore W2979897420C2781413609 @default.
• W2979897420 hasConceptScore W2979897420C30481170 @default.
• W2979897420 hasConceptScore W2979897420C36394416 @default.
• W2979897420 hasConceptScore W2979897420C53226629 @default.
• W2979897420 hasConceptScore W2979897420C54355233 @default.
• W2979897420 hasConceptScore W2979897420C55493867 @default.
• W2979897420 hasConceptScore W2979897420C71924100 @default.
• W2979897420 hasConceptScore W2979897420C86803240 @default.
• W2979897420 hasConceptScore W2979897420C90924648 @default.
• W2979897420 hasIssue "22" @default.
• W2979897420 hasLocation W29798974201 @default.
• W2979897420 hasOpenAccess W2979897420 @default.

• next